CSL Ltd.

NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. Deutsche Bank offers a very broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings. * This information was provided by CSL Limited (January 2026). Depositary Receipt Information Depositary Receipt Contacts Country Australia New Business Development Nicole Pfundstein Custodian Bank BNP Paribas S.A., Level 6, 60 Castlereagh Street, Sydney NSW 2000 Tel: +61 2 8258 1019 Markets Distribution adr@db.com London Effective Date January 27, 2026 Tel: +44 (0) 20 7547 6500 gtb.db.com New York Level I ADR Tel: +1 212 250 9100 CUSIP 12637N204 ISIN US12637N2045 Symbol CSLLY Exchange OTC Current Ratio 2 ADSs: 1 ordinary share Eligibility DTC Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany’s leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific. The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© January 2026 Deutsche Bank AG. All rights reserved. Contacts For further information, please contact: Deutsche Bank AG Press & Media Relations Dylan Riddle Tel. +12122504982 Cell. +1(904)3866481 Email dylan.riddle@db.com

Concerns that Kennedy would inject vaccine skepticism into the U.S. health apparatus were rife before he was confirmed to head up the Department of Health and Human Services (HHS) early last year. While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizer’s CEO cut to the chase this week in a blatant rebuke of HHS Secretary Robert F. Kennedy Jr., according to The Wall Street Journal.“I have very productive discussions when it comes to cancer cures, when it comes to the ‘most-favored nations’ deal, et cetera,” Pfizer’s Albert Bourla said during a WSJ event at the World Economic Forum in Davos, Switzerland. “It’s a different world when you start discussing vaccines, there’s almost like a religion there,” the CEO said, as quoted by the newspaper.On the topic of what would need to change for discussions on vaccines to advance in the U.S., Bourla responded, “[t]he Secretary of Health,” according to the Journal. The Pfizer chief also described Kennedy's vaccine position as “anti-science” during the event.Bourla's position marks a pivot from where he stood in late 2024, when he said he'd developed a “good relation with Mr. Kennedy” during a dinner at then-President-elect Donald Trump's Mar-a-Lago residence. Adding to the reasons for his confidence in the future of U.S. immunization policy, Bourla highlighted his “very long-lasting relationship” with President Trump and the COVID-19 vaccine Pfizer developed with government support through Operation Warp Speed during Trump's first term. Despite this assurance, concerns that Kennedy would inject vaccine skepticism into the U.S. health apparatus were rife before he was confirmed to head up the Department of Health and Human Services (HHS) early last year. In fact, to secure a key confirmation vote from Senator Bill Cassidy, Kennedy reportedly made a promise to “work within the current vaccine approval and safety monitoring systems,” the senator said at the time. But in the year since then, Kennedy's oversight of the U.S. vaccine infrastructure has prompted regular criticism from the senator.In June, Kennedy’s HHS ousted all 17 sitting members of the CDC’s Advisory Committee on Immunization Practices (ACIP), which helps the CDC make vaccine recommendations. He then swiftly restaffed the panel with controversial new members, some of whom are skeptical of vaccine safety and efficacy.The revamped ACIP has subsequently been mired in controversy and condemnation from major U.S. medical organizations, such as the American Academy of Pediatrics, which have accused the panel of making politicized recommendations more rooted in ideology than science. Besides the situation at ACIP, the CDC this month overhauled the United States' longstanding childhood vaccine schedule, removing prior broad vaccination recommendations for COVID, influenza, rotavirus, meningitis, hepatitis A and hepatitis B.The change followed calls from President Trump for the HHS and acting CDC director Jim O’Neill to compare the U.S.’ childhood vaccination schedule to those of peer nations. The assessment found that the U.S. is a “global outlier among developed nations” in terms of the number of diseases addressed and total doses recommended for kids, the CDC said earlier this month. Kennedy’s politicized influence at HHS and its constituent agencies has also been made clear in the high-profile departures of several federal health officials last year.Notably, Peter Marks, M.D., Ph.D.—who last year resigned abruptly from his leadership position at the FDA’s Center for Biologics Evaluation and Research (CBER), which oversees vaccines—told the Associated Press that he’d faced pressure to step aside after attempting to block Kennedy from unfettered access to the federal vaccine safety database known as VAERS.In a scathing resignation letter, Marks argued that he tried to compromise with Kennedy before realizing that “truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies.”Bourla isn't the only CEO of a vaccine-focused drugmaker to express exasperation at Kennedy in recent weeks. During a media breakfast at the J.P. Morgan Healthcare Conference last week, Sanofi helmsman Paul Hudson noted that vaccine policy changes in the U.S. fall in line with what his company was expecting in the build-up to the 2024 election. “I've had conversations with Kennedy; we just try to stick to the facts,” Hudson explained at the event. “Not much we can do.”In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally while declining in the U.S., with Sanofi's CFO François Roger even remarking upon the "negative buzz" around vaccines on a conference call at the time. The vaccine sales decline was even more pronounced among companies that specialize in immunizations, such as Moderna and CSL, which backtracked plans to spin out its vaccine division last year due to the "heightened volatility in the current U.S. influenza vaccine market," according to the Australian company's chairman Brian McNamee. Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut funding to U.S. universities, framing the issue in terms of the U.S.’ health innovation race with China.“We have a meteoric rise of Chinese innovation,” the Pfizer CEO said. “They are producing serious innovation, serious science.” He also critiqued efforts by the U.S. to slow the roll of innovation coming out of China, arguing that “[y]ou can’t stop China. And you shouldn’t.” Instead, Bourla encouraged governments to adopt policies that boost their own competitiveness.“Are you going to slow [China] down in discovering new cancer medicines? Why, what is the benefit to humanity?” Bourla asked. 

Febrile seizures can occur after childhood vaccinations and typically last no more than a few minutes and are generally harmless. The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of the risk of febrile seizures, which can occur after childhood vaccinations and typically last no more than a few minutes and are generally harmless.The FDA sent the notifications to Sanofi, AstraZeneca, GSK and CSL Seqirus earlier this month. Each of the six vaccines has been on the market in the U.S. for at least 13 years, including Sanofi’s Fluzone, which was blessed by the agency in 1980. Other shots cited in the letters, which were sent on January 9, were AZ’s FluMist, GSK’s Fluarix and FluLaval, and CSL’s Afluria and Flucelvax.In the notices (PDF) to the companies, the FDA wrote that two postmarketing observational studies conducted by the FDA's Biologics Effectiveness and Safety System (BEST) revealed an increased risk of febrile seizures on the first day following vaccination in children aged 6 months to 4 years.The flu shots were assessed over two flu seasons, from 2023 to 2025, using three commercial insurance claim data sources, the U.S. regulator told the companies. Among children ages 6 months to 4 years, the risk of febrile seizures within a window of 0 to 1 days after vaccination was compared to the risk within a control window of 8 to 63 days after vaccination, the FDA said.The FDA did not include full data in the notifications, but did say that information from one data partner indicated an estimated risk of 21 febrile seizure episodes for every 1 million quadrivalent vaccinations. For trivalent vaccinations from the same data partner, the estimated rate was 44 seizures for every 1 million shots, the FDA said.A spokesperson for Sanofi said that of the billions of doses of Fluzone that have been administered, febrile seizures have occurred in a “limited subset of patients.” The company already includes information on febrile seizures in its current prescribing information for the shot.“Sanofi maintains an ongoing commitment to robust safety surveillance and effectiveness monitoring, informed by clinical and postmarketing data,” the spokesperson wrote in an email. “The existing data continue to support the established safety and efficacy profile of Fluzone SD.”A GSK spokesperson said that the company is reviewing the FDA's label update request.“Our top priority is patient safety,"  the spokesperson added. "We are committed to monitoring and ensuring the safety of all our products, including our seasonal influenza vaccines, and we are confident in their safety and efficacy profile."The FDA wants companies to use the following language on their labels: “In two separate postmarketing observational studies, an increased risk of febrile seizures was observed during the first day following vaccination with standard dose trivalent (2024-2025) and quadrivalent (2023-2024) influenza vaccines in children 6 months through 4 years of age.” The FDA has given the companies 30 days to agree to include the suggested label update, propose changes to the notice, or submit a rebuttal explaining why a change is not needed.Earlier this month, the CDC removed broad recommendations for flu shots for children in a sweeping move in which the U.S. health agency upended the childhood immunization schedule, also eliminating recommendations for other vaccines that protect them from diseases including COVID-19, rotavirus, meningitis, hepatitis A and hepatitis B.Additionally, immunization against respiratory syncytial virus (RSV)—the top cause for infant hospitalizations in the U.S., according to the CDC—is now limited to those at high risk and children whose mothers have not been vaccinated. Vaccines have been under heightened scrutiny since Robert F. Kennedy Jr., a longtime anti-vaccine activist, took over at the Department of Health and Human Services. Last year, RFK Jr. removed all 17 former experts on the CDC’s Advisory Committee on Immunization Practices and replaced them with his own selections.Sanofi's spokesperson warned that flu can pose “significant health risks, particularly for young children under 5 and individuals with specific pre-existing health conditions.” The American Academy of Pediatrics recommends annual flu vaccination for all pediatric patients aged 6 months and older who do not have a contraindication, the spokesperson said.Infectious disease experts have warned that opting out of a universal recommendation for childhood flu shots could endanger those who are at a higher risk of complications.